Gastric Restriction Using the EndoSurgical Operating System

Sponsor
USGI Medical (Industry)
Overall Status
Terminated
CT.gov ID
NCT01661608
Collaborator
(none)
32
5
1
13
6.4
0.5

Study Details

Study Description

Brief Summary

The primary objective is to collect data on the use of the EndoSurgical Operating System (EOS) for gastric tissue approximation during primary gastric restrictive procedures.

Condition or Disease Intervention/Treatment Phase
  • Device: Using the EOS for gastric restriction
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Gastric Restriction Using the EndoSurgical Operating System
Study Start Date :
Dec 1, 2008
Actual Primary Completion Date :
Jan 1, 2010
Actual Study Completion Date :
Jan 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: EOS

Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures

Device: Using the EOS for gastric restriction

Outcome Measures

Primary Outcome Measures

  1. Clinical Evaluation in regards to Weight Loss [24 Months Post-op]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patient has met diabetic lab testing and all pre-procedural qualifications as delineated below.

  • Patient is >/= 20 yrs. of age and </= 60 yrs. of age

  • Patient has a BMI of >/=30 and < 40

  • Patient has history of obesity for >/= 2 yrs.

  • Patient has had not significant weight change (<5% of total body weight) in last 6 months.

  • Patient is a reasonable candidate for general anesthesia

  • Patient agrees not to have any additional weight loss surgery or liposuction for 2 yrs. following procedure.

Exclusion Criteria:
  • Patient is not able and willing to return for all follow-up evaluations, tests and nutritional counseling.

  • Patient is not able to provide written informed consent

  • Patient has history or present use of insulin or insulin derivatives for treatment of diabetes.

  • Patient has diabetes secondary to a specific disease.

  • Patient has history of inflammatory disease of GI tract

  • Patient has diabetic retinopathy

  • Patient has chronic pancreatic disease

  • Patient ahs active peptic ulcer

  • Patient has portal hypertension

  • Patient has esophageal varices

  • Patient has significant esophageal disease

  • Patient has a history of any significant abdominal surgery

  • Patient has a history of any bariatric or GERD surgical procedures

  • Patient has a hiatal hernia > 2cm.

  • Patient has esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments

  • Patient is of childbearing age and not practicing effective birth control method, pregnant or lactating.

  • Patient has had a MI or CVA in last year, or has unstable cardiovascular disease.

  • Patient has cancer or life expectancy of < 2 yrs.

  • Patient currently uses or has used over the counter or prescription weight loss drugs in last month or intends to use during follow-up Registry period.

  • Patient has quit smoking within last 6 months or plans to quit smoking in the next year.

  • Patient has a history of durg or alcohol abuse

  • Patient has uncontrolled depression, psychosis, or eating disorder.

  • Patient is non-ambulatory or has significant impairment of mobility.

  • Patient has known hormonal or genetic cause for obesity.

  • Patient is participating in another Registry and/or Study that could adversely affect this Registry.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bluegrass Lexington Kentucky United States
2 SSL New Orleans Louisiana United States
3 Brigham & Womens Boston Massachusetts United States
4 Presbyterian Charlotte North Carolina United States
5 Mexico Mexico City Mexico

Sponsors and Collaborators

  • USGI Medical

Investigators

  • Principal Investigator: Michael J. Thomas, MD, FACS, SSL
  • Principal Investigator: Thomas Lavin, MD, SSL
  • Principal Investigator: David Voelinger, MD, Presbyterian
  • Principal Investigator: Peter Denk, MD, Bluegrass
  • Principal Investigator: Christopher Thompson, MD, Brigham & Womans
  • Principal Investigator: Santiago Horgan, MD, UCSD

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
USGI Medical
ClinicalTrials.gov Identifier:
NCT01661608
Other Study ID Numbers:
  • TPR41122
First Posted:
Aug 9, 2012
Last Update Posted:
Aug 9, 2012
Last Verified:
Aug 1, 2012
Keywords provided by USGI Medical

Study Results

No Results Posted as of Aug 9, 2012